Alicia Michaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alicia Michaud has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Petr O. Ilyinskii
Selecta Biosciences , Watertown, MA 02472 , USA
3 shared publications - Sheldon S. Leung
Selecta Biosciences , Watertown, MA 02472 , USA
3 shared publications - Takashi Kei Kishimoto
Selecta Biosciences, Watertown, MA, USA
3 shared publications - Teresa Capela
Selecta Biosciences , Watertown, MA 02472 , USA
3 shared publications - Christopher J. Roy
Selecta Biosciences, Watertown, MA, 02472, USA
2 shared publications Gina Rizzo
Selecta Biosciences , Watertown, MA 02472 , USA
2 shared publications
Latest Publications
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (11) , pgad394
Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents
Tolerogenic ImmTOR nanoparticles encapsulating rapamycin have been demonstrated to mitigate immunogenicity of adeno-associated virus (AAV) gene therapy vectors, enhance levels of transgene expression, and enable redosing of AAV at moderate vector doses of 2 to 5E12 vg/kg. However, recent clinical trials have often pushed AAV vector doses 10-fold to 50-fold higher, with serious adverse events observed at the upper range. Here, we assessed combination therapy of ImmTOR with B cell-targeting drugs for the ability to increase the efficiency of redosing at high vector doses. The combination of ImmTOR with a monoclonal antibody against B cell activation factor (aBAFF) exhibited strong synergy leading to more than a 5-fold to 10-fold reduction of splenic mature B cells and plasmablasts while increasing the fraction of pre-/pro-B cells. In addition, this combination dramatically reduced anti-AAV IgM and IgG antibodies, thus enabling four successive AAV administrations at doses up to 5E12 vg/kg and at least two AAV doses at 5E13 vg/kg, with the transgene expression level in the latter case being equal to that observed in control animals receiving a single vector dose of 1E14 vg/kg. Similar synergistic effects were seen with a combination of ImmTOR and a Bruton's tyrosine kinase inhibitor, ibrutinib. These results suggest that ImmTOR could be combined with B cell-targeting agents to enable repeated vector administrations as a potential strategy to avoid toxicities associated with vector doses above 1E14 vg/kg.
- 1 November 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (11) , pgad394
Open AccessReadministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents
Tolerogenic ImmTOR nanoparticles encapsulating rapamycin have been demonstrated to mitigate immunogenicity of adeno-associated virus (AAV) gene therapy vectors, enhance levels of transgene expression, and enable redosing of AAV at moderate vector doses of 2 to 5E12 vg/kg. However, recent clinical trials have often pushed AAV vector doses 10-fold to 50-fold higher, with serious adverse events observed at the upper range. Here, we assessed combination therapy of ImmTOR with B cell-targeting drugs for the ability to increase the efficiency of redosing at high vector doses. The combination of ImmTOR with a monoclonal antibody against B cell activation factor (aBAFF) exhibited strong synergy leading to more than a 5-fold to 10-fold reduction of splenic mature B cells and plasmablasts while increasing the fraction of pre-/pro-B cells. In addition, this combination dramatically reduced anti-AAV IgM and IgG antibodies, thus enabling four successive AAV administrations at doses up to 5E12 vg/kg and at least two AAV doses at 5E13 vg/kg, with the transgene expression level in the latter case being equal to that observed in control animals receiving a single vector dose of 1E14 vg/kg. Similar synergistic effects were seen with a combination of ImmTOR and a Bruton's tyrosine kinase inhibitor, ibrutinib. These results suggest that ImmTOR could be combined with B cell-targeting agents to enable repeated vector administrations as a potential strategy to avoid toxicities associated with vector doses above 1E14 vg/kg.
- Open Access
- 14 October 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 140, 103125
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease
- 14 October 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 140, 103125
Open AccessRapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease
- Open Access
- 26 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (9) , eabd0321
Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
Liver-directed AAV transgene expression is enhanced by ImmTOR nanoparticles.
- 26 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (9) , eabd0321
Open AccessEnhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
Liver-directed AAV transgene expression is enhanced by ImmTOR nanoparticles.